donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
HAE Haemonetics
63.990
-0.960-1.48%
YOY
Do not show
Hide blank lines
(FY)2022/04/02(Q4)2022/04/02(Q3)2022/01/01(Q2)2021/10/02
Total revenue
14.1% 993.2M 17.76% 265M 259.77M 14.52% 239.9M
Operating revenue
14.1% 993.2M 17.76% 265M -- 259.77M 14.52% 239.9M
Cost of revenue
3.19% 487.69M -10.15% 128.69M 121.2M 13.12% 117.36M
Gross profit
27.06% 505.5M 66.63% 136.31M 138.57M 15.88% 122.54M
Operating expense
27.63% 433.78M 12.94% 116.54M 102.91M 24.94% 98.03M
Selling and administrative expenses
23.84% 339.56M 9.71% 91.84M -- 80.73M 5.69% 75.78M
Research and development costs
42.44% 46.8M 21.83% 13.21M -- 10.04M 60.48% 10.85M
Depreciation amortization depletion
44.42% 47.41M 33.13% 11.48M -- 12.15M -- 11.4M
-Depreciation and amortization
44.42% 47.41M 33.13% 11.48M -- 12.15M -- 11.4M
Operating profit
23.74% 71.72M 192.52% 19.78M 35.65M -10.17% 24.51M
Net non-operating interest income expense
-1.7% -17.12M 37.77% -3.87M -4.26M -19.92% -4.59M
Non-operating interest expense
1.7% 17.12M -37.77% 3.87M -- 4.26M 19.92% 4.59M
Other net income (expense)
-71.6% 9.03M -389.95% -577K
Special income (charges)
-71.6% 9.03M -389.95% -577K -- 0 -- 0
-Less:Impairment of capital assets
-- 577K -- -- -- -- -- --
-Write off
-- -- -- 577K -- -- -- --
-Gain on sale of business
-70.73% 9.6M -- 0 -- 0 -- 0
Income before tax
-12.73% 63.63M 155.94% 15.33M 31.39M -63.75% 19.92M
Income tax
408.94% 20.25M 134.15% 5.59M 8.16M -26.1% 5.07M
Net income
-45.42% 43.38M 188.23% 9.74M 23.23M -69.11% 14.86M
Net income continuous Operations
-45.42% 43.38M 188.23% 9.74M -- 23.23M -69.11% 14.86M
Minority interest income
Net income attributable to the parent company
-45.42% 43.38M 188.23% 9.74M 23.23M -69.11% 14.86M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-45.42% 43.38M 188.23% 9.74M 23.23M -69.11% 14.86M
Basic earnings per share
-45.86% 0.85 187.76% 0.1906 0.45 -69.47% 0.29
Diluted earnings per share
-45.81% 0.84 186.36% 0.19 0.45 -69.15% 0.29
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
Unqualified Opinion with Explanation------

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital’s blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient’s overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
CEO: Simon, Christopher A.
Market: NYSE
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...